At Biotech Showcase 2022, Glooko COO Komathi Stem discussed how real world data, digital platforms and AI help pharmaceutical companies create therapies that address cardiometabolic diseases.

Glooko CEO Russ Johannesson predicts that the growth in digital health funding will continue in 2022, and that the push toward interoperability will be critical for the space.

Russ Johannesson, CEO of diabetes management company Glooko, looks back on the trends in digital health last year—including the explosion of funding—and discusses what’s next for the space as we start 2022.

Glooko was included in a report that highlights the burgeoning industry of continuous glucose monitoring and where it’s likely to head next.

Glooko was named a leader in diabetes digital therapeutics for healthcare payers by CB Insights. The ranking reinforces the company’s commitment to providing a high-quality digital diabetes management platform.

Seemingly overnight, healthcare discovered and fully embraced digital health solutions. Just months after the 2020 nationwide lockdown, telehealth visits, virtual clinical trials and countless remote patient care technologies became the new normal.

The aftershocks of COVID-19 continue to reverberate throughout the U.S. healthcare system. For example, the pandemic has forever dispelled the quaint notion that “real” healthcare can only occur in hospitals and clinics. By drastically restricting in-person visits, COVID-19 has forced healthcare providers to find new ways to remotely engage, monitor, manage, and treat patients.

The pandemic has set ablaze the white-hot market for Digital Therapeutics (DTx), which “deliver medical interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of diseases and disorders.”

In recent years, there has been a great deal of talk in healthcare circles about remote patient monitoring (RPM), a trend that has only accelerated over the past 18 months with the arrival of COVID-19 and the need, early in the pandemic, to transfer a great deal of care to remote delivery.

In this episode of Medtech Matters, a podcast focused on the medical device manufacturing industry and the factors impacting it, we speak with Russ Johannesson, CEO of Glooko. He speaks about the advantages remote monitoring offers to both physicians of diabetics as well as the patients themselves.